Nona Biosciences
A global biotech committed to providing integrated antibody discovery services, ranging from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation.
Nona is leveraging advantages of Harbour Mice technology to achieve this; Harbour Mice generate fully human monoclonal antibodies in a traditional two heavy and two light chain (H2L2) format, and a heavy chain only (HCAb) format. The company hopes to deveop next-generation drugs by integrating Harbour Mice with highly robust antibody screening platforms.
Latest Nona Biosciences News & Features
15 December 2023
15 November 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze